Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.
It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.
Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | -0.89 Increased by +59.55% | -0.97 Increased by +8.25% |
| Aug 1, 24 | -0.80 Increased by +63.47% | -1.29 Increased by +37.98% |
| May 2, 24 | 1.40 Increased by +165.12% | -1.66 Increased by +184.34% |
| Feb 15, 24 | -1.82 Increased by +31.32% | -2.04 Increased by +10.78% |
| Oct 26, 23 | -2.20 Increased by +1.35% | -2.37 Increased by +7.17% |
| Aug 2, 23 | -2.19 Increased by +18.28% | -2.54 Increased by +13.78% |
| May 4, 23 | -2.15 Decreased by -20.11% | -2.67 Increased by +19.48% |
| Feb 16, 23 | -2.65 Increased by +50.93% | -2.65 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 128.18 M Increased by +126.61% | -56.28 M Increased by +57.91% | Decreased by -43.90% Increased by +81.43% |
| Jun 30, 24 | 138.16 M Increased by +139.98% | -49.99 M Increased by +62.35% | Decreased by -36.19% Increased by +84.31% |
| Mar 31, 24 | 96.12 M Increased by +51.87% | 89.14 M Increased by +168.80% | Increased by +92.74% Increased by +145.30% |
| Dec 31, 23 | 71.96 M Increased by +85.55% | -110.92 M Increased by +30.08% | Decreased by -154.14% Increased by +62.32% |
| Sep 30, 23 | 56.57 M Decreased by -14.26% | -133.71 M Decreased by -0.41% | Decreased by -236.38% Decreased by -17.12% |
| Jun 30, 23 | 57.57 M Increased by +57.52% | -132.79 M Increased by +16.85% | Decreased by -230.66% Increased by +47.22% |
| Mar 31, 23 | 63.29 M Increased by +0.89% | -129.56 M Decreased by -22.23% | Decreased by -204.72% Decreased by -21.15% |
| Dec 31, 22 | 38.78 M Decreased by -63.76% | -158.64 M Increased by +50.22% | Decreased by -409.06% Decreased by -37.37% |